Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Venn Life Sciences Holdings Plc LSE:VENN London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 6.85 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
6.70 7.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 12.52 -4.50 -6.57 5
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 6.85 GBX

Venn Life Sciences (VENN) Latest News

More Venn Life Sciences News
Venn Life Sciences Investors    Venn Life Sciences Takeover Rumours

Venn Life Sciences (VENN) Discussions and Chat

Venn Life Sciences Forums and Chat

Date Time Title Posts
02/7/201912:10one to follow for great potential is VENN1,484
14/3/201916:35Venn Life Sciences 38
24/3/201619:04Venn Life Sciences......rapid growth and potential !294

Add a New Thread

Venn Life Sciences (VENN) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Venn Life Sciences trades in real-time

Venn Life Sciences (VENN) Top Chat Posts

DateSubject
02/12/2020
08:20
Venn Life Sciences Daily Update: Venn Life Sciences Holdings Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker VENN. The last closing price for Venn Life Sciences was 6.85p.
Venn Life Sciences Holdings Plc has a 4 week average price of 0p and a 12 week average price of 0p.
The 1 year high share price is 0p while the 1 year low share price is currently 0p.
There are currently 71,395,148 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Venn Life Sciences Holdings Plc is £4,890,567.64.
24/6/2019
09:40
sja123: https://www.proactiveinvestors.co.uk/companies/stocktube/13813/venn-life-sciences-to-put-open-orphan-merger-to-shareholders-next-thursday-13813.html
21/6/2019
11:07
yump: Apparently VENN was 'under-capitalised'. That's why their revenue dropped, although there isn't any explanation of exactly how that process worked. No quotes of 'this that and the other potential client wouldn't give us the contract because our balance sheet looked rubbish'. Believe that and you'll believe anything. 'Orphan drugs': the ones nobody will touch because they require government or other subsidy (new shareholders ??) to make them commercially viable.
13/6/2019
19:37
aishah: Venn Life Sciences – shares restored at a massive premium… but much more to come httPs://www.shareprophets.com/views/43117/venn-life-sciences-shares-restored-at-a-massive-premium-but-much-more-to-come
13/6/2019
19:31
jpuff: So what's the verdict on the corporate action? (Given I'm an existing long suffering holder of Venn)?
11/6/2019
07:19
cocker: I agree and although it has served me well Buywell I still am not 100% convinced that the constant dilutions are in the interest of shareholders. I sold my remaining few shares of 35k in Venn 1st thing as TU wasn't impressive
10/5/2019
18:40
cocker: Wait for it, share placing @ 50% discount to current share price Trying to buy its self out of trouble with another related transaction. Richardson if you're reading this, you really are a useless C@@T & anyone wanting to invest here most be ready for the lunatic asylum.
10/5/2019
06:45
jpuff: AIM Suspension - Venn Life Sciences Holdings PlcSource: UK Regulatory (RNS & others)TIDMVENNRNS Number : 5713YAIM10 May 2019NOTICE10/05/2019 7:30amTEMPORARY SUSPENSION OF TRADING ON AIMVENN LIFE SCIENCES HOLDINGS PLCAt the request of the Company trading on AIM for the under-mentioned securities has been temporarily suspended from 10/05/2019 7:30am, pending publication of an admission document and an announcement.ORDINARY SHARES OF 0.1P EACH FULLY PAID (B9275X9) (GB00B9275X97)If you have any queries relating to the above, please contact the company's nominated adviser on +44 (0)20 7614 5900.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDEXCZMGGKKLKGLZM(END) Dow Jones NewswiresMay 10, 2019 02:30 ET (06:30 GMT)
25/1/2019
21:40
cocker: This company has gone from 20p+ - 1.5p in a very short time because it has failed miserably. The past maybe no guide to the future, but with Richardson's guidence Venn has almost exhausted every financial avenue available to them, thus why the last one in December is with private individuals with a 10% coupon. Related transactions which are still promenant with SKIN and it seems a business model that is flawed, it remains a very risky punt. I understand the attraction of bottom fishing and if it works for you, then well done. But, when the share price has risen 0.5p let's not get carried away, Venn is being run for the purpose of lining its directors pockets & until they prove otherwise, I won't be investing.
11/12/2018
11:59
rivaldo: For the record from the analyst at Davy this morning.... Https://www.davy.ie/research/public/article.htm?id=ST2_12746_1.xml.htm "DAVY VIEW Venn’s strategic collaboration with Open Orphan should feed through into new business opportunities in the high growth orphan (rare) disease market – an area of strong focus for Venn. The principles of Open Orphan will be joining Venn’s Board – Professor Brendan Buckley was previously Chief Medical Officer for ICON and brings a wealth of experience and a business network that should benefit Venn. The new financing consisting of £1m loan notes means more capital is available for Venn to invest in the business and possible M&A. Our FY 2018 and FY 2019 revenue forecasts are now €13.8m and €16.5m respectively. Our FY 2018 and FY 2019 EBITDA forecasts are -€0.5m and €0.4m respectively."
22/8/2017
08:48
rivaldo: Cheers basem, appreciated. Personally I follow the fundamentals, and they're telling me that VENN is fundamentally undervalued. That will be the case even if VENN fails to achieve Hybridan's forecast £1.27m adjusted PBT, which I'm not sure they will. If VENN were to achieve only 50% of that - say a £600k PBT - if you combine that with the almost €3m cash pile, the investment in SKIN and the value of the core business as outlined in my post 1005 then VENN is worth considerably more than the current share price. In a small-cap like this, one or two larger sellers can easily drive the share price down to silly levels given the propensity of others to follow them out on a drifting share price, the hitting of stop-losses etc. I believe that's what happened here. As spooky says, it looks like the share price has hit a bottom and is starting to lift itself off that bottom now. The solid H1 update and the confidence for the full year should continue this into and onwards from the H1 results next month.
Venn Life Sciences share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
VENN
Venn Life ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201203 08:13:55